Openbookopenbook
Equity
EW
+0.0 · +0.00%
USD · NYSE

Edwards Lifesciences Corp(EW) Stock Analysis | Healthcare

USD --+0.00%
Reward50Moderate
Risk26Low
75%Data
Strong 15% profit margin · Revenue growing 14% YoY
Quality Compounder
Market Cap:51.75Bn
ⓘ
Reward Rating
50
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
26
Low
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on EW to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for EW, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $100.96.

What is Edwards Lifesciences Corp?

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.

EW · Verdict

Moderate reward · low risk

EW stands out on balance sheet and cash flow, but watch the valuation signal.

Based on 88% data coverage

EW · Verdict

What’s working & what to watch

Strengths 3

  • Balance sheet99/100

    Interest covered 62.4×

  • Cash flow91/100

    22% free-cash-flow margin

  • Profitability77/100

    18% net margin · 9% ROE

Watchouts 1

  • Valuation23/100

    P/E 29.9× · PEG 2.16

Model-based scoring. For information only — not financial advice.

What is Edwards Lifesciences Corp?

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 51.75B, and a P/E ratio of 53.4x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (50)

The scoring profile indicates limited reward potential at this time, with profitability and momentum offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

SEMHFLarge Cap / 56.5B market cap
Siemens Healthineers AG
Compare
BSXLarge Cap / 73B market cap
Boston Scientific Corp
Compare
DXCMLarge Cap / 34.8B market cap
DexCom Inc
Compare
Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap51.75B
P/E Ratio53.4464
Dividend YieldN/A
Beta0.846
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
662,058 shares
$5.1M
0
6-9months
767,804 shares
$5.7M
0
9-12months
214,020 shares
$1.2M
0
5 disclosures without share count
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.